Bioanalysis Of Unstable Analytes In Pharmacokinetic Be Studies For Andas Bioanalysis 2020

Summary

Zhen Zhang, CDER Office of Generic Drugs, explains the regulatory requirements for stability and how to identify and resolve ... Tian Ma, CDER Office of Generic Drugs, summarize common reasons/codes of Director of the Office of Translational Sciences (OTS) ShaAvhrée Buckman-Garner, MD, PhD, FAAP, opened the meeting ... Arindam Dasgupta, Deputy Director, Division of New Drug Zhen Zhang and Tian Ma from the CDER Office of Generic Drugs respond to audience questions. FDA CDER's Small Business ... Diaa Shakleya, CDER Office of Pharmaceutical Quality (OPQ), discusses Sriram Subramaniam, CDER Office of Clinical Pharmacology, discusses Presenters Patrick Faustino, Jinhui Zhang, and Diaa Shakleya respond to audience questions. FDA CDER's Small Business and ... Ruben Ayala, CDER Office Translational Sciences, discusses Salaheldin S. Hamed, CDER Office of Clinical Pharmacology, provides an introduction to biosimilars to include submission ... Jinhui Zhang, CDER Office of Pharmaceutical Quality, discusses the Biologics Price Competition and Innovation Act (BPCI) Act ... Melkamu Getie-Kebtie, CDER Office of Drs. Leah Falade and Suman Dandamudi from CDER's Office of Generic Drugs discuss what to expect during FDA